Hahn Fields Queries On Electrical Stim Devices, Molybdenum Supplies For Imaging At FDA Confirmation Hearing

MD Anderson Cancer Center chief medical officer Stephen Hahn fielded a number of questions senators asked at his 20 November confirmation hearing to lead the US FDA. Chief among them were inquiries about his government experience level, whether he would expedite a ban on electrical stimulation devices used against the intellectually disabled, and how he would address a shortage of molybdenum-99 used in advanced imaging scans.

Stephen Hahn, President Trump’s nominee for commissioner of the FDA, at his Senate confirmation hearing
FDA Commissioner nominee Stephen Hahn, standing, pulls out a chair in preparation for his Senate confirmation hearing • Source: Derrick Gingery

More from Leadership

More from Medtech Insight